# ChanPharm

> ChanPharm GmbH is a Vienna-based contract research organisation (CRO) specialising in ion channel screening for drug discovery. We provide automated and manual patch clamp, cardiac safety (CiPA / hERG) studies, neurotoxicity screening, and stem cell (iPSC) studies on SyncroPatch 384, Patchliner, multi-electrode arrays (MEA), and high-speed sCMOS imaging platforms. Led by Prof. Steffen Hering with 45+ years of ion-channel pharmacology experience.

## Core Services

- [Ion Channel Screening](https://chanpharm.com/ion-channel-screening/): Automated and manual patch clamp screening covering hERG, Nav, Cav, Kv, KCa, GABA-A, NMDA, TRPA1 and custom targets. Up to 20,000 data points per day on SyncroPatch 384.
- [Cardiac Safety Studies](https://chanpharm.com/cardiac-safety-services/): CiPA-aligned hERG screening and full cardiac ion channel panel — hERG, Nav1.5, Cav1.2, Cav3.2, Kir2.1, Kv4.3, Kv7.1. SyncroPatch 384, Patchliner, MEA, and iPSC cardiomyocyte assays.
- [Neurotoxicity Services](https://chanpharm.com/neurotoxicity-services/): iPSC-derived neurons, multi-electrode array (MEA) network assays, and patch clamp recordings for early CNS and peripheral toxicity detection. Seizurogenic liability screening at hit-to-lead stage.
- [Stem Cell Studies](https://chanpharm.com/stem-cell-studies/): Human iPSC-derived cardiomyocytes and neurons — patch clamp, MEA, sCMOS imaging, and 3D microtissue (spheroid / organoid) assays for drug discovery and safety profiling.
- [CiPA Multichannel Safety Panel](https://chanpharm.com/cipa-screening/): Validated CiPA ion channel screening panel covering all reference channels (hERG, Nav1.5 peak+late, Cav1.2, Cav3.2, Kir2.1, Kv4.3/KChIP, Kv7.1/MinK) for drug-induced arrhythmia risk assessment.
- [In Silico Cardiotoxicity Prediction](https://chanpharm.com/insilico-cardiotoxicity/): Ventricular action-potential modelling integrating multi-channel patch-clamp IC50 data for CiPA-aligned proarrhythmia risk evaluation.

## Platforms & Instruments

- [SyncroPatch 384](https://chanpharm.com/syncropatch-384/): High-throughput automated patch clamp by Nanion Technologies. Up to ~20,000 giga-seal data points per day for primary screening, safety pharmacology, and ion channel drug discovery.
- [Patchliner](https://chanpharm.com/patchliner/): Medium-throughput automated patch clamp by Nanion. Giga-seal recordings for secondary screening, lead optimisation, and mechanism-of-action studies.
- [Manual Patch Clamp](https://chanpharm.com/manual-patch-clamp/): Gold-standard whole-cell recordings in human iPSC-derived sensory neurons and native tissue for detailed ion channel pharmacology and kinetics.
- [Multi-Electrode Array (MEA)](https://chanpharm.com/mea/): Network-level electrophysiology in 24- and 96-well formats. High-throughput cardiac safety screening, neuronal network analysis, and field potential recordings.
- [Kinetix sCMOS Imaging](https://chanpharm.com/kinetix-imaging/): High-speed fluorescence imaging up to 498 fps with 96% quantum efficiency. Calcium and voltage-sensitive dye imaging, cardiac contractility assays.

## Ion Channel Targets

- [Voltage-Gated Sodium Channels (Nav1.1–Nav1.9)](https://chanpharm.com/sodium-channels/): Drug targets for analgesic and antiepileptic drug discovery. Particular focus on Nav1.7, Nav1.8, Nav1.9.
- [Kv1.x Family](https://chanpharm.com/kv1x-family/): Kv1.3 (autoimmune, metabolic, oncology), Kv1.5 (atrial fibrillation) potassium channel screening.
- [Kv7.2 / Kv7.3 (KCNQ M-current)](https://chanpharm.com/kv7273/): Potassium channels relevant for epilepsy, pain, and CNS drug discovery.
- [KCa3.1 (IKCa1, SK4)](https://chanpharm.com/kca3_1/): Intermediate-conductance calcium-activated potassium channels — inflammatory, autoimmune, fibrotic, vascular drug discovery.
- [T-type Calcium Channels (Cav3.1–Cav3.3)](https://chanpharm.com/t-type-calcium-channels/): Cav3.2 in particular for neuropathic pain, epilepsy, and cardiovascular disorders.
- [GABA-A Receptors](https://chanpharm.com/gabaa/): Subtype-selective modulators for anxiety, epilepsy, sleep, and CNS drug discovery (benzodiazepine site).
- [NMDA Receptors (GluN1/GluN2B)](https://chanpharm.com/nmda-receptor/): GluN2B subtype-selective antagonists for neuroprotection, depression, neurological disorders.
- [TRPA1](https://chanpharm.com/trpa1/): Transient Receptor Potential channel for novel analgesic and anti-inflammatory drug discovery.
- [Custom Ion Channel Assays](https://chanpharm.com/other-targets/): Custom assay development for emerging targets — TRPV1, TRPM8, P2X receptors, ASICs, HCN channels, two-pore-domain potassium channels.

## Team

- [Team Overview](https://chanpharm.com/team/): All team members.
- [Prof. Steffen Hering](https://chanpharm.com/team-hering/): Founder & CEO. 45+ years of ion-channel pharmacology research.
- [Dr. Igor Baburin](https://chanpharm.com/team-baburin/): Head of Patch Clamp Services. Expert in automated and manual patch clamp electrophysiology.
- [Dr. Stanislav Beyl](https://chanpharm.com/team-beyl/): Head of Business Development & Data Analysis. Leads strategic partnerships and collaborations; specialist in electrophysiology data processing, ion channel kinetics, and computational modelling.
- [Dr. Ilayda Soztekin](https://chanpharm.com/team-soztekin/): Head of Patch Clamp Unit. Specialist in automated patch clamp electrophysiology.
- [Dr. Clara Hoebart](https://chanpharm.com/team-hoebart/): Head of Cardiotoxicity Team. Specialist in CiPA-aligned cardiac safety pharmacology.
- [MSc. Sara Meschini](https://chanpharm.com/team-meschini/): Head of Quality Management. Expert in quality systems for contract research.

## Resources

- [FAQ](https://chanpharm.com/faq/): 21 questions across categories — Services & Capabilities, Technology & Platforms, Engagement & Logistics, Quality & Data.
- [Contact](https://chanpharm.com/contact/): Email office@chanpharm.com, phone +43-660-223-2203. Headquartered Vienna, Austria.

## Company

ChanPharm GmbH
- Headquarter: Leidesdorfgasse 14, Top 6, 1190 Vienna, Austria
- Research Facility: Am Kanal 27, Top 2|3|5, 1110 Vienna, Austria
- Email: office@chanpharm.com
- Phone: +43-660-223-2203 / +43-(0)1-997-80-51
- LinkedIn: https://www.linkedin.com/company/chanpharm/
- Founded: 2014 by Prof. Steffen Hering
- Service area: Worldwide (pharmaceutical and biotech clients globally)

## Key Differentiators

1. Depth of analysis — reports include full biophysical interpretation (voltage-dependence, state-dependent block, kinetics, mechanism-of-action), not just IC50/EC50 values.
2. Flexibility — protocols, solutions, and pulse paradigms adapted to specific scientific questions rather than fixed assay templates.
3. Detailed reporting — raw traces, fitted curves, methodology, QC summaries, expert discussion. Significantly more detailed than typical industry reports.
4. Fast project starts — standard hERG and single-target screening projects typically begin within 1 week of compound receipt.
5. Custom assay development capability — emerging targets, custom cell lines, custom protocols.